Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Stem Cell Procurement

G-CSF mobilized vs conventional donor lymphocytes for therapy of relapse or incomplete engraftment after allogeneic hematopoietic transplantation

Bone Marrow Transplantation volume 48, pages 357–362 (2013)Cite this article

Subjects

Abstract

There is little data comparing the activity and toxicity of donor lymphocyte therapy with granulocyte (G)-CSF-mobilized cells (G-donor lymphocyte infusion (DLI)) with the conventionally collected DLI (C-DLI) after allogeneic blood or marrow transplantation. We retrospectively evaluated 67 patients to compare the efficacy and toxicity of GCSF-mobilized DLI with C-DLI in the treatment of relapse of malignant disease or poor donor engraftment post transplant. We assessed clinical outcomes that may represent the immunological outcome of DLI. The median OS was 210 days (range 3–2436 days), 291 days (range 17–1491 days) in the G-DLI group (15 patients) and 207.5 days (range 3–2436 days) in the C-DLI group (52 patients). The median PFS time was 72 days (range 8–1491 days) in the G-DLI group vs 82 days (range 1–2436 days) in the C-DLI group. Rates of post DLI GVHD and improvement in donor engraftment were similar in the G-DLI and C-DLI groups. We conclude that G-DLI appears to have similar therapeutic activity to that seen with C-DLI, and where such cells are available they may be substituted for conventional donor lymphocytes.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Copelan EA, Biggs JC, Thompson JM, Crilley P, Szer J, Kapoor N et al. Treatment for acute myelocytic leukemia with allogeneic bone marrow transplantation following preparation with BuCy2. Blood 1991; 78: 838–843.

    CAS  PubMed  Google Scholar 

  2. Frassoni F, Barrett AJ, Grañena A, Ernst P, Garthon G, Kolb HJ et al. Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the E.B.M.T. of 117 cases. Br J Haematol 1988; 70: 317–320.

    CAS  PubMed  Google Scholar 

  3. Schmid C, Labopin M, Nagler A, Bornhäuser M, Fnke J, Fassas A et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol 2007; 25: 4938–4945.

    Article  CAS  PubMed  Google Scholar 

  4. Mortimer J, Blinder MA, Schulman S, Appelbaum FR, Buckner CD, Clift RA et al. Relapse of acute leukemia after marrow transplantation: natural history and results of subsequent therapy. J Clin Oncol 1989; 7: 50–57.

    Article  CAS  PubMed  Google Scholar 

  5. Slavin S, Naparstek E, Nagler A, Ackerstein A, Samuel S, Kapelushnik J et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood 1996; 87: 2195–2204.

    CAS  PubMed  Google Scholar 

  6. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041–2050.

    CAS  PubMed  Google Scholar 

  7. Bensinger WI, Martin PJ, Storer B, Clift R, Forman SJ, Negrin R et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001; 344: 175–181.

    Article  CAS  PubMed  Google Scholar 

  8. Couban S, Simpson DR, Barnett MJ, Bredeson C, Hubesch L, Howson-Jan K et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002; 100: 1525–1531.

    Article  CAS  PubMed  Google Scholar 

  9. Flowers ME, Parker PM, Johnston LJ, Matos AV, Storer B, Bensinger WI et al. Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. Blood 2002; 100: 415–419.

    Article  CAS  PubMed  Google Scholar 

  10. Klangsinsirikul P, Russell NH . Peripheral blood stem cell harvests from G-CSF-stimulated donors contain a skewed Th2 CD4 phenotype and a predominance of type 2 dendritic cells. Exp Hematol 2002; 30: 495–501.

    Article  CAS  PubMed  Google Scholar 

  11. Kolb HJ, Mittermuller J, Clemm C, Holler E, Ledderose G, Brehm G et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462–2465.

    CAS  PubMed  Google Scholar 

  12. Collins RH, Rogers ZR, Bennett M, Kumar V, Nikein A, Fay JW et al. Hematologic relapse of chronic myelogenous leukemia following allogeneic bone marrow transplantation: apparent graft-versus-leukemia effect following abrupt discontinuation of immunosuppression. Bone Marrow Transplant 1992; 10: 391–395.

    PubMed  Google Scholar 

  13. Mackinnon S, Papadopoulos EB, Carabasi MH, Reich L, Collins NH, Boulad F et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261–1268.

    CAS  PubMed  Google Scholar 

  14. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C . Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000; 18: 1360–1377.

    Article  CAS  PubMed  Google Scholar 

  15. Kiss JE, Rybka WB, Winkelstein A, de Magalhaes-Silverman M, Lister J, D’Andrea P et al. Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 1997; 19: 303–310.

    Article  CAS  PubMed  Google Scholar 

  16. Guglielmi C, Arcese W, Dazzi F, Brand R, Bunjes D, Verdonck LF et al. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose. Blood 2002; 100: 397–405.

    Article  CAS  PubMed  Google Scholar 

  17. Collins RHJ, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997; 15: 433–444.

    Article  PubMed  Google Scholar 

  18. Dazzi F, Szydlo RM, Craddock C, Cross NC, Kaeda J, Chase A et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000; 95: 67–71.

    CAS  PubMed  Google Scholar 

  19. Dazzi F, Szydlo RM, Cross NC, Craddock C, Kaeda J, Kanfer E et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood 2000; 96: 2712–2716.

    CAS  PubMed  Google Scholar 

  20. Schattenberg A, Schaap N, Van De Wiel-Van Kemenade E, Bär B, Preijers F, Van Der Maazen R et al. In relapsed patients after lymphocyte depleted bone marrow transplantation the percentage of donor T lymphocytes correlates well with the outcome of donor leukocyte infusion. Leuk Lymphoma 1999; 32: 317–325.

    Article  CAS  PubMed  Google Scholar 

  21. Dazzi F, Szydlo RM, Apperley JF, Goldman JM . Prognostic factors for acute graft-versus-host disease after donor lymphocyte infusions. Blood 2002; 100: 2673–2674.

    Article  PubMed  Google Scholar 

  22. Huff CA, Fuchs EJ, Smith BD, Blackford A, Garrett-Mayer E, Brodsky RA et al. Graft-versus-host reactions and the effectiveness of donor lymphocyte infusions. Biol Blood Marrow Transplant 2006; 12: 414–421.

    Article  PubMed  Google Scholar 

  23. Fozza C, Szydlo RM, Abdel-Rehim MM, Nadal E, Goldman JM, Apperley JF et al. Factors for graft-versus-host disease after donor lymphocyte infusions with an escalating dose regimen: lack of association with cell dose. Br J Haematol 2007; 136: 833–836.

    Article  CAS  PubMed  Google Scholar 

  24. Verdonck LF, Petersen EJ, Lokhorst HM, Nieuwenhuis HK, Dekker AW, Tilanus MG et al. Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells. Bone Marrow Transplant 1998; 22: 1057–1063.

    Article  CAS  PubMed  Google Scholar 

  25. Lokhorst HM, Schattenberg A, Cornelissen JJ, Van Oers MH, Fibbe W, Russell L et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome. J Clin Oncol 2000; 18: 3031–3037.

    Article  CAS  PubMed  Google Scholar 

  26. Jun HX, Jun CY, Yu ZX . In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor. Haematologica 2004; 89: 1517–1524.

    CAS  PubMed  Google Scholar 

  27. Chen SH, Li X, Huang XJ . Effect of recombinant human granulocyte colony-stimulating factor on T-lymphocyte function and the mechanism of this effect. Int J Hematol 2004; 79: 178–184.

    Article  CAS  PubMed  Google Scholar 

  28. Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C . Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000; 95: 2484–2490.

    CAS  PubMed  Google Scholar 

  29. Pan L, Delmonte J, Jalonen CK, Ferrara JL . Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995; 86: 4422–4429.

    CAS  PubMed  Google Scholar 

  30. Zeng D, Jbakhsh-Jones S, Strober S . Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: impact on blood progenitor cell transplantation. Blood 1997; 90: 453–463.

    CAS  PubMed  Google Scholar 

  31. Krenger W, Snyder KM, Byon JC, Falzarano G, Ferrara JL . Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease. J Immunol 1995; 155: 585–593.

    CAS  PubMed  Google Scholar 

  32. Krenger W, Cooke KR, Crawford JM, Sonis ST, Simmons R, Pan L et al. Transplantation of polarized type 2 donor T cells reduces mortality caused by experimental graft-versus-host disease. Transplantation 1996; 62: 1278–1285.

    Article  CAS  PubMed  Google Scholar 

  33. Fowler DH, Kurasawa K, Smith R, Eckhaus MA, Gress RE . Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood 1994; 84: 3540–3549.

    CAS  PubMed  Google Scholar 

  34. Imami N, Brookes PA, Lombardi G, Hakooz B, Johns M, Goldman JM et al. Association between interleukin-4-producing T lymphocyte frequencies and reduced risk of graft-versus-host disease. Transplantation 1998; 65: 979–988.

    Article  CAS  PubMed  Google Scholar 

  35. Pan L, Teshima T, Hill GR, Bungard D, Brinson YS, Reddy VS et al. Granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation maintains graft-versus-leukemia effects through a perforin-dependent pathway while preventing graft-versus-host disease. Blood 1999; 93: 4071–4078.

    CAS  PubMed  Google Scholar 

  36. Reyes E, Garcia-Castro L, Esquivel F, Hornedo J, Cortes-Funes H, Solovera J et al. Granulocyte colony-stimulating factor (G-CSF) transiently suppresses mitogen-stimulated T-cell proliferative response. Br J Cancer 1999; 80: 229–235.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Mielcarek M, Graf L, Johnson G, Torok-Storb B . Production of interleukin-10 by granulocyte colony-stimulating factor-mobilized blood products: a mechanism for monocyte-mediated suppression of T-cell proliferation. Blood 1998; 92: 215–222.

    CAS  PubMed  Google Scholar 

  38. Eckardt JR, Roodman GD, Boldt DH, Clark GM, Alvarez R, Page C et al. Comparison of engraftment and acute GVHD in patients undergoing cryopreserved or fresh allogeneic BMT. Bone Marrow Transplant 1993; 11: 125–131.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, PA, USA

    K K S Abbi, J Zhu, W C Ehmann, E Epner, M Carraher, J Mierski, G Talamo, K Lucas, W Rybka & D Claxton

Authors
  1. K K S Abbi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W C Ehmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E Epner
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Carraher
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J Mierski
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G Talamo
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. K Lucas
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. W Rybka
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. D Claxton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D Claxton.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abbi, K., Zhu, J., Ehmann, W. et al. G-CSF mobilized vs conventional donor lymphocytes for therapy of relapse or incomplete engraftment after allogeneic hematopoietic transplantation. Bone Marrow Transplant 48, 357–362 (2013). https://doi.org/10.1038/bmt.2012.144

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2012.144

Keywords

Search

Advanced search

Quick links